Cargando…
Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/ https://www.ncbi.nlm.nih.gov/pubmed/35891184 http://dx.doi.org/10.3390/vaccines10071020 |
_version_ | 1784754659972349952 |
---|---|
author | Zhang, Yuntao Chen, Haiping Lv, Jun Huang, Tao Zhang, Ruizhi Zhang, Dongjuan Luo, Linyun Wei, Sheng Liu, Xiaoqin Zhang, Shangxiao Mu, Qiuyue Huang, Rongdong Huang, Jiao Xiao, Yanhui Yang, Yunkai Han, Yuting Gong, Hao Guan, Qinghu Xie, Fangqin Wang, Hui Li, Liming Yang, Xiaoming |
author_facet | Zhang, Yuntao Chen, Haiping Lv, Jun Huang, Tao Zhang, Ruizhi Zhang, Dongjuan Luo, Linyun Wei, Sheng Liu, Xiaoqin Zhang, Shangxiao Mu, Qiuyue Huang, Rongdong Huang, Jiao Xiao, Yanhui Yang, Yunkai Han, Yuting Gong, Hao Guan, Qinghu Xie, Fangqin Wang, Hui Li, Liming Yang, Xiaoming |
author_sort | Zhang, Yuntao |
collection | PubMed |
description | Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in the diabetes group, 300 in the hypertensive combined with diabetes group (combined disease group), and 480 in the healthy population group. Two doses of the COVID-19 vaccine (Vero cell), inactivated, were administered at a 21-day interval and blood samples were collected before vaccination and 28 days after the second dose to evaluate the immunogenicity. The adverse events and changes in blood pressure and blood glucose levels after vaccination were recorded. Results: The seroconversion rate of the COVID-19 neutralizing antibodies was 100% for all participants. The post-inoculation geometric mean titer (GMT) in the four groups of the hypertension, diabetes, combined disease, and healthy populations were 73.41, 69.93, 73.84, and 74.86, respectively. The seroconversion rates and post-vaccination GMT in the hypertension, diabetes, and combined disease groups were non-inferior to the healthy population group. The rates of vaccine-related adverse reactions were 11.93%, 14.29%, 12.50%, and 9.38%, respectively. No serious adverse events were reported during the study. No apparent abnormal fluctuations in blood pressure and blood glucose values were observed after vaccination in participants with hypertension or(/and) diabetes. Conclusions: The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus. |
format | Online Article Text |
id | pubmed-9315836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93158362022-07-27 Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus Zhang, Yuntao Chen, Haiping Lv, Jun Huang, Tao Zhang, Ruizhi Zhang, Dongjuan Luo, Linyun Wei, Sheng Liu, Xiaoqin Zhang, Shangxiao Mu, Qiuyue Huang, Rongdong Huang, Jiao Xiao, Yanhui Yang, Yunkai Han, Yuting Gong, Hao Guan, Qinghu Xie, Fangqin Wang, Hui Li, Liming Yang, Xiaoming Vaccines (Basel) Article Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in the diabetes group, 300 in the hypertensive combined with diabetes group (combined disease group), and 480 in the healthy population group. Two doses of the COVID-19 vaccine (Vero cell), inactivated, were administered at a 21-day interval and blood samples were collected before vaccination and 28 days after the second dose to evaluate the immunogenicity. The adverse events and changes in blood pressure and blood glucose levels after vaccination were recorded. Results: The seroconversion rate of the COVID-19 neutralizing antibodies was 100% for all participants. The post-inoculation geometric mean titer (GMT) in the four groups of the hypertension, diabetes, combined disease, and healthy populations were 73.41, 69.93, 73.84, and 74.86, respectively. The seroconversion rates and post-vaccination GMT in the hypertension, diabetes, and combined disease groups were non-inferior to the healthy population group. The rates of vaccine-related adverse reactions were 11.93%, 14.29%, 12.50%, and 9.38%, respectively. No serious adverse events were reported during the study. No apparent abnormal fluctuations in blood pressure and blood glucose values were observed after vaccination in participants with hypertension or(/and) diabetes. Conclusions: The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus. MDPI 2022-06-25 /pmc/articles/PMC9315836/ /pubmed/35891184 http://dx.doi.org/10.3390/vaccines10071020 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Yuntao Chen, Haiping Lv, Jun Huang, Tao Zhang, Ruizhi Zhang, Dongjuan Luo, Linyun Wei, Sheng Liu, Xiaoqin Zhang, Shangxiao Mu, Qiuyue Huang, Rongdong Huang, Jiao Xiao, Yanhui Yang, Yunkai Han, Yuting Gong, Hao Guan, Qinghu Xie, Fangqin Wang, Hui Li, Liming Yang, Xiaoming Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title | Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title_full | Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title_fullStr | Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title_full_unstemmed | Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title_short | Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus |
title_sort | evaluation of immunogenicity and safety of vero cell-derived inactivated covid-19 vaccine in older patients with hypertension and diabetes mellitus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315836/ https://www.ncbi.nlm.nih.gov/pubmed/35891184 http://dx.doi.org/10.3390/vaccines10071020 |
work_keys_str_mv | AT zhangyuntao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT chenhaiping evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT lvjun evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT huangtao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT zhangruizhi evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT zhangdongjuan evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT luolinyun evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT weisheng evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT liuxiaoqin evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT zhangshangxiao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT muqiuyue evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT huangrongdong evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT huangjiao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT xiaoyanhui evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT yangyunkai evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT hanyuting evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT gonghao evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT guanqinghu evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT xiefangqin evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT wanghui evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT liliming evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus AT yangxiaoming evaluationofimmunogenicityandsafetyofverocellderivedinactivatedcovid19vaccineinolderpatientswithhypertensionanddiabetesmellitus |